Understanding Corona Remedies IPO: Everything a beginner investor needs to know about bidding dates, price band, financial performance, and why this pharmaceutical company is expanding into the stock market.
Table of Contents
Corona Remedies is stepping into the public eye with its Initial Public Offering (IPO), and if you are new to investing, this could be an exciting opportunity to learn how IPOs work in the real world. Let’s break down everything about this pharmaceutical company in simple, easy to understand terms.
Who is Corona Remedies?
Corona Remedies is a pharmaceutical company based in Ahmedabad, Gujarat that was founded in 2004. The company has grown from a startup with minimal investment into one of India’s most dynamic pharmaceutical businesses. Founded by Dr. Kirtikumar Laxmidas Mehta, who holds over 36 years of experience in the medical industry, the company is now led by his son Niravkumar Kirtikumar Mehta as the Managing Director and Chief Executive Officer. Niravkumar recently received the prestigious 2024 Hurun Industry Achievement Award for his contributions to the pharmaceutical sector.
The company manufactures a wide range of medicines including tablets, capsules, syrups, ointments, and injectable products designed to treat various medical conditions. Corona Remedies currently has about 4,573 permanent employees and operates manufacturing facilities in Gujarat and Himachal Pradesh, with plans to launch a new hormone production facility in Gujarat.
Corona Remedies IPO Overview
Key Facts at a Glance
| Category | Details |
|---|---|
| Company | Pharma firm founded in 2004, based in Ahmedabad |
| Leadership | Dr. K. L. Mehta (Founder), Niravkumar Mehta (MD & CEO) |
| Business Focus | 71 brands across women’s health, cardio-diabeto, pain, urology |
| Growth | Domestic sales grew 13.58% vs industry 7.90% (2024–25) |
| Financials | Revenue: ₹891 cr (2023) → ₹1,202 cr (2025); PAT: ₹85 cr → ₹149 cr |
| IPO Dates | Bidding: Dec 8–10, 2025; Listing: Dec 15, 2025 |
| Price Band | ₹1,008–₹1,062 per share |
| Lot Size | 14 shares minimum; ~₹14,868 at upper band |
| Issue Size | ₹655.37 cr (100% Offer for Sale) |
| Investor Allocation | QIB 50%, Retail 35%, NII 15% |
| Ownership | Promoters 72.5%, institutions 27.5% |
What Does Corona Remedies Make?
Corona Remedies focuses on specific areas of medicine. As of June 2025, the company has a portfolio of 71 brands across several therapeutic segments. The company is particularly strong in women’s healthcare, which contributes about 29 percent of its revenue. The other major focus areas include cardio-diabeto (heart and diabetes medicines) contributing about 23 percent, pain management contributing about 12 percent, and urology products contributing about 5 percent.
The company has been growing faster than the overall Indian pharmaceutical market. Between June 2024 and June 2025, Corona Remedies’ domestic sales grew at an annual rate of 13.58 percent, while the entire Indian pharmaceutical market grew at only 7.90 percent. This means Corona Remedies is growing nearly twice as fast as the industry average.
Understanding the IPO Details
An IPO is when a private company invites the public to buy shares and become part owners of the business. Here are the key dates and numbers you need to know about Corona Remedies IPO:
The bidding period runs from December 8 to December 10, 2025, and the stock is expected to list on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on December 15, 2025. Anchor investors, which are typically large financial institutions that bid before regular investors, had their bidding on December 5, 2025.
The Price Band and Investment Amount
The company has set a price band between 1,008 rupees and 1,062 rupees per share. The face value of each share is 10 rupees, which simply means the printed value on the certificate. The actual price you pay can be anywhere between the lower price of 1,008 rupees and the upper price of 1,062 rupees, depending on how much investor demand there is.
If you are a regular retail investor, the minimum number of shares you can buy is 14 shares. At the highest price of 1,062 rupees per share, this means your minimum investment would be 14,868 rupees. The maximum you can apply for as a retail investor is 13 lots, which equals 182 shares, totaling about 1,93,284 rupees.
Total Issue Size and Offer Structure
Corona Remedies is raising a total of 655.37 crore rupees through this IPO. The entire amount is an Offer for Sale, which means existing shareholders and company founders are selling their shares to the public. The company itself will not receive any money from this IPO since it is not issuing new shares but rather existing shareholders are selling.
The shares are divided among different investor categories. Qualified Institutional Buyers, such as mutual funds and banks, can receive up to 50 percent of the shares. Retail individual investors like you can receive 35 percent, while non-institutional investors can get 15 percent.
Three Years of Growth and Strong Profits
Looking at the company’s financial performance shows a healthy growing business. In the financial year ending March 2023, Corona Remedies had revenue from operations of 891.10 crore rupees. This grew to 1,020.93 crore rupees by March 2024, and reached 1,202.35 crore rupees by March 2025.
More impressive is the profit the company made. In March 2023, the profit after tax was 84.93 crore rupees. By March 2024, this increased to 90.50 crore rupees. But the big jump came in March 2025 when profit after tax surged to 149.43 crore rupees, which is a 65 percent increase from the previous year. This means the company is not only growing its sales but also becoming much more profitable, which is a very positive sign for investors.
Why Investors Might Find This Interesting
Corona Remedies is ranked 17th in the Indian pharmaceutical market by size, but it is growing much faster than larger competitors. The company focuses on important areas like women’s healthcare and diabetes treatment, which are growing segments in India. The company also has a strong sales team with 2,671 medical representatives spread across 22 states, helping it reach doctors and hospitals effectively.
The company has also made smart acquisitions to grow faster. In July 2025, Corona Remedies acquired seven brands from Bayer, including brands for heart conditions and women’s health treatments. These acquisitions show the company’s ability to expand its product range and market position.
Additionally, Corona Remedies has received certifications like FDA, GMP, and ISO, which means its manufacturing meets global quality standards. The company also holds EU GMP certification, indicating it can potentially expand to European markets in the future.
Who Are the Current Owners?
Currently, the promoters and their family members hold 72.50 percent of the company, while institutional investors hold 27.50 percent. Sepia Investments, a private equity firm, holds a significant stake. When this IPO completes, public investors like you will own a portion of the company alongside these existing shareholders.
Key Timeline to Remember
Mark these dates on your calendar if you are thinking of bidding. You can bid between December 8 and December 10, 2025. The company will decide who gets how many shares on December 11. You will receive your money back or the shares will credit to your demat account on December 12. Trading will begin on December 15, 2025.
Conclusion
Corona Remedies is entering the market at a time when investors are paying close attention to companies with steady growth, strong financials, and clear long-term direction. The company checks many of those boxes. It has expanded consistently across key therapeutic segments, built a strong sales network, and delivered impressive profit growth over the past three years. Its focus on women’s health, cardio-diabeto care, and pain management places it in areas where patient demand is rising year after year.
The IPO itself is structured as an Offer for Sale, which means the company isn’t raising fresh capital, but it does open the door for more diverse shareholders and greater visibility in the public markets. The price band and lot size make it accessible for retail investors who want exposure to a growing pharmaceutical business. The company’s certifications and recent brand acquisitions add another layer of confidence, showing that it is preparing for both domestic expansion and potential international opportunities.
For beginners, this IPO offers a practical case study: a mid-sized pharma company with strong leadership, rising profits, and a clear strategic path. While every investment carries risk, Corona Remedies presents a story of measured growth and solid execution that many new investors may find worth exploring.
Source: Corona Remedies IPO Details & Corona Remedies Ltd IPO
Read Also: Nephrocare Health IPO: Should You Apply For This Dialysis Leader? & Understanding the Wakefit IPO: A Complete Guide for Everyday Investors
